![François Martelet](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
François Martelet
Hoofd Techniek/Wetenschap/O&O bij
SCANDION ONCOLOGY A/S
Profiel
Dr. François R.
Martelet is a Chief Medical Officer at Scandion Oncology A/S, an Independent Director at Novigenix SA and a Senior Advisor at Ennovance Capital LLC.
He is on the Board of Directors at Novigenix SA. Dr. Martelet was previously employed as a Chief Executive Officer by Vivesto AB, a Chief Executive Officer & Executive Director by NetScientific Plc, a Chief Executive Officer by Topotarget A/S, a President & Chief Executive Officer by AVAX Technologies, Inc., a Vice President & Global Franchise Head-Oncology by Merck & Co., Inc., a Head-Regional Pharma by Novartis AG, a Chairman by Glycotest, Inc., a Chairman by ProAxsis Ltd., a Senior Vice President-International Operations by Stallergenes SAS, and a Chairman by Vortex BioSciences, Inc. He received his graduate degree from Burgundy School of Business, an MBA from the University of Dijon and a doctorate degree from the University of Dijon.
Actieve functies van François Martelet
| Bedrijven | Functie | Begin |
|---|---|---|
| SCANDION ONCOLOGY A/S | Hoofd Techniek/Wetenschap/O&O | - |
Ennovance Capital LLC
 Ennovance Capital LLC Investment ManagersFinance Ennovance Capital invests in middle market companies located in the United States. The firm focuses on companies operating in the fields of chemicals, allied products, healthcare and related specialty material sectors. It provides financing for growth stage capital requirements with investment size of USD 200 million and above. | Corporate Officer/Principal | 27-01-2010 |
Novigenix SA
 Novigenix SA Medical SpecialtiesHealth Technology Develops molecular diagnostics for cancer | Directeur/Bestuurslid | 18-06-2019 |
Eerdere bekende functies van François Martelet
| Bedrijven | Functie | Einde |
|---|---|---|
| VIVESTO AB | Algemeen Directeur | 21-07-2022 |
| EMV CAPITAL PLC | Algemeen Directeur | 30-04-2019 |
| TOPOTARGET A/S | Algemeen Directeur | 30-08-2012 |
| AVAX TECHNOLOGIES, INC. | Algemeen Directeur | 01-01-2009 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01-12-2006 |
Opleiding van François Martelet
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
65
Eerstegraads connecties
16
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 16 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
AVAX Technologies, Inc.
 AVAX Technologies, Inc. BiotechnologyHealth Technology Operates as development stage company with interest in the development and future commercialization of individualized cancer vaccines | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Stallergenes SA
 Stallergenes SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products used for the treatment of allergy-related respiratory diseases | Health Technology |
Topotarget A/S
 Topotarget A/S Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceuticals | Health Technology |
Vivesto AB
 Vivesto AB Pharmaceuticals: GenericHealth Technology Develops cancer drugs based on nanotechnology for human and veterinary use | Health Technology |
University of Dijon
 University of Dijon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EMV Capital Plc
 EMV Capital Plc Medical SpecialtiesHealth Technology Identifies, develops and commercializes transformative biomedical & healthcare technologies | Health Technology |
Ennovance Capital LLC
Ennovance Capital LLC Investment ManagersFinance Ennovance Capital invests in middle market companies located in the United States. The firm focuses on companies operating in the fields of chemicals, allied products, healthcare and related specialty material sectors. It provides financing for growth stage capital requirements with investment size of USD 200 million and above. | Finance |
Université de Paris 5 René Descartes
 Université de Paris 5 René Descartes Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Burgundy School of Business
 Burgundy School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novigenix SA
Novigenix SA Medical SpecialtiesHealth Technology Develops molecular diagnostics for cancer | Health Technology |
Vortex BioSciences, Inc.
 Vortex BioSciences, Inc. Medical SpecialtiesHealth Technology Develops a novel liquid biopsy automated instrument and micro fluidic cartridge for the isolation of circulating tumor cells | Health Technology |
Glycotest, Inc.
 Glycotest, Inc. Electronic Equipment/InstrumentsElectronic Technology Develops unique and non-invasive blood tests for liver cancers and fibrosis-cirrhosis | Electronic Technology |
ProAxsis Ltd.
 ProAxsis Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products through online store | Health Technology |
Scandion Oncology A/S
 Scandion Oncology A/S Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for chemotherapy resistance mechanisms | Health Technology |
